Feature

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief


 


Underscoring the federal government’s position, Health & Human Services Secretary Alex Azar recently pronounced that there was “no such thing as medical marijuana.”

Scientists say that stance prevents them from conducting the high-quality research required for Food and Drug Administration approval, even as some early research indicates marijuana might be a promising alternative to opioids or other medicines.

Patients and physicians, meanwhile, lack guidance when making decisions about medical treatment for an array of serious conditions.

“We have the federal government and the state governments driving a hundred miles an hour in the opposite direction when they should be coming together to obtain more scientific data,” said Orrin Devinsky, MD, who is researching the effects of cannabidiol, an active ingredient of marijuana, on epilepsy. “It’s like saying in 1960, ‘We’re not going to the moon because no one agrees how to get there.’ ”

The problem stems partly from the fact that the federal government’s restrictive marijuana research policies have not been overhauled in more than 40 years, researchers say.

Pages

Recommended Reading

Opioid deaths in the ED increase nationally
MDedge Neurology
Nonopioid analgesics have no major disadvantages vs. opioids for chronic pain
MDedge Neurology
Opioid prescriptions got shorter in 2017
MDedge Neurology
The case for being open-minded about medical marijuana
MDedge Neurology
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Neurology
Is kratom the answer to the opioid crisis?
MDedge Neurology
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Neurology
Sensitivity of vibration-based neuropathy detectors varies widely
MDedge Neurology
Epilepsy upped risk of unnatural death
MDedge Neurology
Life and health are not even across the U.S.
MDedge Neurology